Literature DB >> 24742150

Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.

Gábor Németh1, Zoltán Greff, Anna Sipos, Zoltán Varga, Rita Székely, Mónika Sebestyén, Zsuzsa Jászay, Szabolcs Béni, Zoltán Nemes, Jean-Luc Pirat, Jean-Noël Volle, David Virieux, Ágnes Gyuris, Katalin Kelemenics, Eva Ay, Janos Minarovits, Susan Szathmary, György Kéri, László Orfi.   

Abstract

Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24742150     DOI: 10.1021/jm401742r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).

Authors:  Caroline M Robb; Jacob I Contreras; Smit Kour; Margaret A Taylor; Mohammad Abid; Yogesh A Sonawane; Muhammad Zahid; Daryl J Murry; Amarnath Natarajan; Sandeep Rana
Journal:  Chem Commun (Camb)       Date:  2017-07-04       Impact factor: 6.222

Review 2.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

3.  Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.

Authors:  Rebekah R Shippy; Xiaochen Lin; Sherry S Agabiti; Jin Li; Brendan M Zangari; Benjamin J Foust; Michael M Poe; Chia-Hung Christine Hsiao; Olga Vinogradova; David F Wiemer; Andrew J Wiemer
Journal:  J Med Chem       Date:  2017-03-01       Impact factor: 7.446

Review 4.  Targeting HIV transcription: the quest for a functional cure.

Authors:  Guillaume Mousseau; Sonia Mediouni; Susana T Valente
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

5.  Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.

Authors:  Jiadi Gao; Cheng Fang; Zhiyan Xiao; Li Huang; Chin-Ho Chen; Li-Ting Wang; Kuo-Hsiung Lee
Journal:  Medchemcomm       Date:  2015-03-01       Impact factor: 3.597

6.  A new motif for inhibitors of geranylgeranyl diphosphate synthase.

Authors:  Benjamin J Foust; Cheryl Allen; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem       Date:  2016-06-10       Impact factor: 3.641

Review 7.  Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Authors:  Steven R Whittaker; Aurélie Mallinger; Paul Workman; Paul A Clarke
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

8.  Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.

Authors:  Yogesh A Sonawane; Margaret A Taylor; John Victor Napoleon; Sandeep Rana; Jacob I Contreras; Amarnath Natarajan
Journal:  J Med Chem       Date:  2016-06-03       Impact factor: 7.446

9.  Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.

Authors:  Valentina Gandin; Alessandro Ferrarese; Martina Dalla Via; Cristina Marzano; Adriana Chilin; Giovanni Marzaro
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

10.  Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistant Staphylococcus aureus.

Authors:  Di Li; Rammohan R Yadav Bheemanaboina; Narsaiah Battini; Vijai Kumar Reddy Tangadanchu; Xian-Fu Fang; Cheng-He Zhou
Journal:  Medchemcomm       Date:  2018-08-01       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.